US Broker Ratings

Ardent Health, Inc. (ARDT) Stock Analysis: Exploring a 39.66% Upside Potential for Savvy Investors

Ardent Health, Inc. (NASDAQ: ARDT), a prominent player in the healthcare sector, has been catching the eye of investors with its robust growth metrics and a..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: A 17.86% Upside Potential Amidst Mixed Financial Signals

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a prominent player in the healthcare sector specializing in medical instruments and supplies, has recently caught the attention of investors due..

Immunocore Holdings plc (IMCR) Stock Analysis: Exploring a Potential 79.71% Upside in the Biotechnology Sector

Immunocore Holdings plc (NASDAQ: IMCR) stands out in the biotechnology sector with a compelling growth narrative and a significant potential upside. As a commercial-stage biotechnology company,..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring a 174% Potential Upside

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is captivating investor interest with its substantial growth potential, as highlighted by an impressive 174% potential upside. Positioned in the healthcare..

Haemonetics Corporation (HAE) Stock Analysis: Exploring a 17.76% Potential Upside in the Medical Device Sector

Haemonetics Corporation (NYSE: HAE) stands as a prominent player in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $3.3 billion,..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Unveiling a 23.5% Upside Potential with Strong Buy Ratings

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is capturing investor attention in the healthcare sector, particularly within the biotechnology industry. With a market capitalization of $3.58 billion, the..

Privia Health Group, Inc. (PRVA) Stock Analysis: Exploring a 32% Upside Potential for Investors

Privia Health Group, Inc. (NASDAQ: PRVA), a prominent player in the healthcare sector, is generating considerable buzz among investors thanks to its promising 32.42% potential upside...

Organon & Co. (OGN) Stock Analysis: Uncovering a 34% Potential Upside in the Healthcare Sector

Organon & Co. (OGN) is an intriguing player in the healthcare sector, particularly within the general drug manufacturing industry. With a market cap of $2 billion,..

Ascentage Pharma Group Internat (AAPG): Investor Outlook with 27.57% Potential Upside

Ascentage Pharma Group International (AAPG), a prominent player in the biotechnology sector, has caught the attention of investors with its significant potential upside. Headquartered in Suzhou,..

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Assessing a 57.82% Upside Potential for Investors

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is capturing the attention of investors with a promising 57.82% potential upside, according to analyst ratings. As a biotechnology company specializing..

Investor Outlook: LivaNova PLC (LIVN) Targets 28.73% Upside – A Healthcare Stock with Growth Potential

LivaNova PLC (NASDAQ: LIVN) stands out in the healthcare sector, specifically within the medical devices industry, where it designs and delivers innovative solutions for neurological and..

AtriCure, Inc. (ATRC) Stock Analysis: Unveiling a Promising 61% Upside Potential

AtriCure, Inc. (NASDAQ: ATRC), an innovative player in the healthcare sector, stands at an intriguing juncture for investors, with a market capitalization of $1.59 billion. Specializing..

NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 16.47% Upside Potential in the Biotechnology Sector

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a leading entity in the biotechnology sector, has recently captured the attention of investors with its compelling growth prospects and..

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Navigating 39.69% Potential Upside Amidst Transformative Drug Discovery

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stands at an intriguing crossroads, offering a potential upside of nearly 39.69% based on its average target price of $6.30. As..

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Navigating a 30.69% Potential Upside

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a prominent player in the biopharmaceutical space, specializes in developing and commercializing treatments for central nervous system (CNS) diseases. Although the..

LifeStance Health Group, Inc. (LFST) Stock Analysis: Exploring a 33% Upside in the Healthcare Sector

LifeStance Health Group, Inc. (NASDAQ: LFST) is carving out a significant niche in the U.S. healthcare sector with its comprehensive suite of outpatient mental health services...

Merus N.V. (MRUS): Investor Outlook on a Promising Biotechnology Contender with a 1.66% Upside Potential

Merus N.V. (NASDAQ: MRUS), a Netherlands-based biotechnology firm, is increasingly capturing the attention of investors, particularly those with a keen eye on the healthcare sector. With..

Zai Lab Limited (ZLAB) Investor Outlook: Navigating a 132% Potential Upside in the Biotech Sector

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the biotechnology sector, is capturing investor attention with an enticing potential upside of 132.25%. This Chinese biopharmaceutical..

ICU Medical, Inc. (ICUI) Stock Analysis: Potential Upside Amidst Strong Analyst Ratings

ICU Medical, Inc. (NASDAQ: ICUI), a prominent player in the medical instruments and supplies industry, offers a compelling investment proposition with its focus on infusion therapy,..

Progyny, Inc. (PGNY) Stock Analysis: 20.66% Potential Upside Beckons Investors in Fertility Benefits Market

Progyny, Inc. (NASDAQ: PGNY), a leader in fertility and family-building benefits solutions, is creating quite a buzz in the healthcare sector, particularly among investors keen on..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds